MF Researcher Database

Researchers Database

Advance

KOMATSU Hirokazu

    Graduate School of Medical Sciences Department of Hematology & Oncology
Contact： komatsumed.nagoya-cu.ac.jp
Last Updated :2024/04/26

Researcher Information

URL

J-Global ID

Research Interests

  • がんゲノム医療   がん薬物療法   希少がん   

Research Areas

  • Life sciences / Hematology and oncology

Education

  •        -   Nagoya City University

Association Memberships

  • Japanese Society of Internal Medicine   Japanese Society of Medical Oncocolgy   Japanese Ｓｏｃｉｅｔｙ ｏｆ Ｈｅｍａｔｏｌｏｇｙ   Japanese Cancer Association   

Published Papers

MISC

Research Grants & Projects

  • Japan Society for the Promotion of Science：Grants-in-Aid for Scientific Research
    Date (from‐to) : 2022/04 -2025/03 
    Author : 大野 裕美; 小松 弘和; 蒔田 寛子
  • Japan Society for the Promotion of Science：Grants-in-Aid for Scientific Research
    Date (from‐to) : 2013/04 -2016/03 
    Author : Komatsu Hirokazu
     
    Cancer patients were shown to need information of cancer and psychological support according to the analysis of cancer consultation. Especially, psychological burden such as anxiety and loneliness was clarified to influence cancer patients seriously through the analysis of carcinoma of unknown primary patients, manifesting metastasis and poor prognosis. In summary, Provision of information of cancer and psychological support should be stressed to gain the QOL and the satisfaction of cancer patients.
  • Japan Society for the Promotion of Science：Grants-in-Aid for Scientific Research
    Date (from‐to) : 2010 -2012 
    Author : FUJII Naoko; TOGARI Hajime; SUZUKI Kenichi; KOMATSU Hirokazu; MORITA Akimichi; ODA Kumiko; IWATA Hiroko; OGURO Chieko; MURASE Hiroshi
     
    An interdisciplinary study team was formed in collaboration with the Nursing Department and the doctors of the Chemotherapy Department of Nagoya City University Hospital in order to develop a study ofpatient clothes worn by hospitalized patients. In this study, we focused on easy removability and improvement of recovery willingness of patients based on the fact-finding research of the current conditions ofpatient clothes. The purpose of this study was to advance our development and study of patient clothing designs that apply retractility brought about by a traditional technique in Nagoya City, Arimatsu-Narumi Shibori(tie-dyeing). The achievements of this study are as follows: （1） Proposal of patient clothes for mid and long term medical treatment based on previous research on patient clothes and treatment environments both at home and abroad （2） Extraction of cases regarding basic patient clothes structures and designs that achieve easy removability （3） Production and verification of patient clothes prototypes that apply Arimatsu-Narumi Shibori（4） Public announcement of the developed patient clothesdesign
  • Japan Society for the Promotion of Science：Grants-in-Aid for Scientific Research
    Date (from‐to) : 2007 -2009 
    Author : UEDA Ryuzo; KOMATSU Hirokazu; ISHIDA Takashi; INAGAKI Hiroshi
     
    We have demonstrated that the anti-CCR4 mAb reduces the number of Treg cells among TIL in an in vivo NOG mouse model (bearing human tumor & engrafted with human immune cells). These results indicate that use of anti-CCR4 mAb could represent a novel strategy for the treatment not only of Hodgkin lymphoma, but also many other types of cancer by overcoming suppressive effects of Treg cells on the host's immune response to tumor cells. In the near future, the efficacy of the anti-CCR4 mAb in the latter context will also be established in clinical trials in humans.
  • Japan Society for the Promotion of Science：Grants-in-Aid for Scientific Research
    Date (from‐to) : 2005 -2009 
    Author : UEDA Ryuzo; SATO Shigeki; KOMATSU Hirokazu; ISHIDA Takashi
     
    CCR4 is a chemokine receptor selectively expressed on Treg and Th2 cells. Because we previously found that CCR4 is expressed on certain types of T-cell leukemia/lymphoma, we postulated that this molecule might represent a novel molecular target for immunotherapy against refractory T-cell leukemia/lymphoma. Accordingly, we have developed a next-generation anti-CCR4 mAb, the Fc region of which is defucosylated, resulting in highly enhanced ADCC. Based on our laboratory work on CCR4, and as an outcome of the success of this translational research, we have completed phase I & II clinical trials of anti-CCR4 mAb in patients with CCR4-positive T-cell leukemia/lymphoma in Japan, and are in the process of preparing an application to the regulatory authority for approval.
  • Japan Society for the Promotion of Science：Grants-in-Aid for Scientific Research
    Date (from‐to) : 2004 -2006 
    Author : UEDA Ryuzo; IIDA Shinsuke; KOMATSU Hirokazu
     
    CCR4 was shown to be expressed in many types of T-cell malignancies, especially in adult T-cell leukemia/lymphoma (ATLL), peripheral T-cell lymphoma-unspecified (PTCL-U) and anaplastic large cell lymphoma (ALK negative) and be a significant and independent prognostic marker in ATLL and PTCL-U. Monoclonal antibody for CCR4 presented a strong anti-tumor effect for several types of T-cell malignancies via ADCC activity in vivo as well as in vitro assay, including CCR4-espressing Hodgkin lymphoma and cutaneous T-cell lymphoma. CCR4 was also expressed in the surface of cells with the character of regulatory T-cells (FOXP3 positive), strongly suggesting that the origin of ATLL tumor cells can be regulatory T-cells. Reactive T-cells surrounding Hodgkin cells (Reed-Sternberg cells) were shown to manifest both CCR4 and FOXP3 expressions on their surfaces, which suggest that CCR4 can be target molecule for the elimination of the anergy for tumor immunity. Phase I clinical study of the humanized monoclonal antibody therapy of CCR4 for T-cell malignancies was conducted and was shown to be well-tolerable with clinical resoponse.
  • Japan Society for the Promotion of Science：Grants-in-Aid for Scientific Research
    Date (from‐to) : 1999 -2001 
    Author : WAKITA Atsushi; KOMATSU Hirokazu; IIDA Shinsuke; UEDA Ryuzo
     
    We investigate 42 members out degree in a family with hereditary essential thrombocythemia. Ten members had already died, and the causes of the deaths are 2 of old age, one brain hemorrage and one cerebral infarction. Eighteen members who alive were received blood examination, essential thrombocythemia was diagnosed for 9 patients. In the essential thrombocythemia patients, the age was 7 to 64 years old. The oldest patients had complication brain hemorrage and he died of second hemorragic attack. On deaths, his bone marrow showed myelofibrosis and platelet count was lower than normal. There was no patients with trombotic or hemorragic complications. Other symptoms resulting from platelet increment were, one patient had headache and one had dizziness, they were not serious. Platelet function test showed decreased ADP aggregation and epinephrine aggregation in the patients, they were normal in the healthy members. Platelet adhesion test was almost normal. Oral mucous sample was harvested from 7 female patients, which were examined clonality analysis using polymorphism of HUMARA gene. There was no evidence of clonal shift in the all seven patients. Sereum thrombopoietin level almost normal in the patients, and completely normal in the healthy members. Analysis of c-Mpl mutaion was daone in two patients. Kown mutations were not detected in our patients.
  • がん薬物療法患者における科学的QOL評価による実地医療への有効な支援法の同定
  • 家族性血小板血症の発症機序の分子生物学的解明

Other link

researchmap


Copyright © MEDIA FUSION Co.,Ltd. All rights reserved.